JP7490559B2 - 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 - Google Patents

抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 Download PDF

Info

Publication number
JP7490559B2
JP7490559B2 JP2020544005A JP2020544005A JP7490559B2 JP 7490559 B2 JP7490559 B2 JP 7490559B2 JP 2020544005 A JP2020544005 A JP 2020544005A JP 2020544005 A JP2020544005 A JP 2020544005A JP 7490559 B2 JP7490559 B2 JP 7490559B2
Authority
JP
Japan
Prior art keywords
seq
set forth
binding protein
lma
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020544005A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514369A (ja
JP2021514369A5 (https=
JPWO2019161443A5 (https=
Inventor
ロザンヌ・ダン
Original Assignee
ハエマロジックス・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900534A external-priority patent/AU2018900534A0/en
Application filed by ハエマロジックス・リミテッド filed Critical ハエマロジックス・リミテッド
Publication of JP2021514369A publication Critical patent/JP2021514369A/ja
Publication of JP2021514369A5 publication Critical patent/JP2021514369A5/ja
Publication of JPWO2019161443A5 publication Critical patent/JPWO2019161443A5/ja
Priority to JP2024079382A priority Critical patent/JP7798956B2/ja
Application granted granted Critical
Publication of JP7490559B2 publication Critical patent/JP7490559B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020544005A 2018-02-20 2019-02-20 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質 Active JP7490559B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024079382A JP7798956B2 (ja) 2018-02-20 2024-05-15 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2018900534A AU2018900534A0 (en) 2018-02-20 Composition and method
AU2018900534 2018-02-20
PCT/AU2019/050137 WO2019161443A1 (en) 2018-02-20 2019-02-20 Anti-lambda myeloma antigen (lma) binding proteins to treat lma-expressing cancer and autoimmune disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024079382A Division JP7798956B2 (ja) 2018-02-20 2024-05-15 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質

Publications (4)

Publication Number Publication Date
JP2021514369A JP2021514369A (ja) 2021-06-10
JP2021514369A5 JP2021514369A5 (https=) 2022-03-02
JPWO2019161443A5 JPWO2019161443A5 (https=) 2022-03-02
JP7490559B2 true JP7490559B2 (ja) 2024-05-27

Family

ID=67686653

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020544005A Active JP7490559B2 (ja) 2018-02-20 2019-02-20 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質
JP2024079382A Active JP7798956B2 (ja) 2018-02-20 2024-05-15 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024079382A Active JP7798956B2 (ja) 2018-02-20 2024-05-15 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質

Country Status (10)

Country Link
US (2) US11447571B2 (https=)
EP (1) EP3755724A4 (https=)
JP (2) JP7490559B2 (https=)
KR (1) KR102824611B1 (https=)
CN (1) CN111918879B (https=)
AU (2) AU2019225446B2 (https=)
BR (1) BR112020017018A2 (https=)
CA (1) CA3091711A1 (https=)
SG (1) SG11202007925SA (https=)
WO (1) WO2019161443A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250326864A1 (en) * 2022-06-13 2025-10-23 Paradox Immunotherapeutics Inc. Monoclonal antibodies targeting conformation-specific epitopes of immunoglobulin light chains of the lambda subclass
WO2025236034A1 (en) * 2024-05-13 2025-11-20 HaemaLogiX Ltd Anti-lma binding proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523913A (ja) 2004-02-27 2007-08-23 パクマブ リミテッド Ｂ細胞疾患の標的
JP2012522811A (ja) 2009-04-07 2012-09-27 イミューン システム セラピューティクス リミテッド 免疫障害を治療する方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100187181A1 (en) * 2009-01-29 2010-07-29 Sortwell Edwin T Method for Dispersing and Aggregating Components of Mineral Slurries
GB201203938D0 (en) * 2012-03-06 2012-04-18 Binding Site Group The Ltd Assay system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007523913A (ja) 2004-02-27 2007-08-23 パクマブ リミテッド Ｂ細胞疾患の標的
JP2012522811A (ja) 2009-04-07 2012-09-27 イミューン システム セラピューティクス リミテッド 免疫障害を治療する方法

Also Published As

Publication number Publication date
CA3091711A1 (en) 2019-08-29
EP3755724A1 (en) 2020-12-30
JP2021514369A (ja) 2021-06-10
CN111918879A (zh) 2020-11-10
US20230174675A1 (en) 2023-06-08
JP2024100838A (ja) 2024-07-26
CN111918879B (zh) 2024-10-15
JP7798956B2 (ja) 2026-01-14
SG11202007925SA (en) 2020-09-29
US12435158B2 (en) 2025-10-07
US20210230309A1 (en) 2021-07-29
WO2019161443A1 (en) 2019-08-29
EP3755724A4 (en) 2022-03-23
BR112020017018A2 (pt) 2020-12-29
AU2021202092A1 (en) 2021-04-29
AU2019225446A1 (en) 2020-10-08
KR102824611B1 (ko) 2025-06-24
US11447571B2 (en) 2022-09-20
KR20210005553A (ko) 2021-01-14
AU2019225446B2 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
US20240182542A1 (en) Multi-Specific Molecules
US11242388B2 (en) ROR1 antibody compositions and related methods
US11078273B2 (en) ROR2 antibody compositions and related methods
US12311031B2 (en) Antibodies specific to CD44
US20220056136A1 (en) Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
AU2019401647A1 (en) Antibodies specific to MUC18
JP7798956B2 (ja) 抗ラムダ骨髄腫抗原（ｌｍａ）発現がん及び自己免疫障害を処置するｌｍａ結合タンパク質
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
EP3131917B1 (en) Humanized and chimeric monoclonal antibodies to cd99
CN121568716A (zh) 抗sp17免疫治疗剂的使用方法
CN121605124A (zh) 编码抗sp17抗体和其他sp17结合蛋白的核酸、载体和细胞
CN113461820B (zh) 抗cd3人源化抗体
CN113461821B (zh) 抗cd3人源化抗体
JP2020508636A (ja) ＩＦＮ−γ誘導性制御性Ｔ細胞転換性抗癌（ＩＲＴＣＡ）抗体およびその使用
CN121646479A (zh) 结合sp17的蛋白质，包括全人源抗sp17抗体
KR102393776B1 (ko) Cd22에 특이적인 인간화 항체 및 이를 이용한 키메라 항원 수용체
HK40061374A (en) Antibodies specific to cd44
CA3105415A1 (en) Antibodies specific to folate receptor alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220218

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220218

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240227

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240515

R150 Certificate of patent or registration of utility model

Ref document number: 7490559

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150